scottrose wrote: Hope the AI assisted mental health program will get Medi-call more subs. They should consider venturing into new areas. It maybe the key to getting more subs, just thinking.

And what else is going on in the AI/Medical Online field around the world?

VANCOUVER, BC / ACCESSWIRE / August 17, 2022 / Sebastiani Ventures Corp. ("Sebastiani" or the "Company") (TSXV:SBS.H) is pleased to announce that it has entered into a binding letter of intent (the "LOI") with EvokAI Creative Labs Inc. ("EvokAI") dated effective August 16, 2022. The LOI outlines the general terms and conditions pursuant to which Sebastiani and EvokAI will effect a business combination that will result in a reverse takeover of Sebastiani by the securityholders of EvokAI (the "Proposed Transaction"). Sebastiani previously entered into a licensing agreement with EvokAI on June 6, 2022, which provided it with the non-exclusive right to pursue strategic partnerships for commercial applications of EvokAI's technology on a worldwide basis. The LOI was negotiated at arm's length.

Assuming completion of the Proposed Transaction, it is anticipated that Sebastiani will graduate to Tier 2 of the TSX Venture Exchange (the "Exchange") as a technology issuer.

EvokAI is a MedTech AI-powered company incorporated in the BVI and headquartered in Allschwil, Switzerland. EvokAI is dedicated to the development of transformational and innovative technologies for the modern healthcare sector. It deploys machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole healthcare system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, to medical professionals, patients, healthy individuals aiming at preventing any kind of disease and beyond, protecting the aging genome.

EvokAI has shown significant advances during the last months, bridging the gap between neuroscience and artificial intelligence, tackling one of the most severe neurodegenerative diseases, Alzheimer's, which is becoming more common as the general population gets older and lives longer, and recently broadening its scope by revolutionizing Parkinson´s Disease analysis and treatment. Entering the MedTech field, this unique novel wireless medical device accurately analyzes the magnitude of movement disorders and the effectiveness of treatments for Parkinson's disease and other movement disorders, a smart device to improve patients' quality of life and support doctors in their work.

For more information about EvokAI, visit the company's website at